Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF Summary
Product Specifications
Gly42-Arg268, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8956-T4
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
When Recombinant Human LILRA5/CD85f is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 of 0.1-0.6 µg/mL.
Reconstitution Calculator
Background: LILRA5/CD85f
The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs) (1). Human LILRA5, also known as ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail (2). The ECD contains two Ig-like domains (3), and the transmembrane segment contains a positively charged aspartic acid residue which may mediate its association with the signaling molecule, FcR common gamma chain (4). Alternative splicing generates additional isoforms with a 12 aa deletion within the signal peptide and/or a 27 aa substitution for the C-terminal 61 residues. This substitution encompasses both the transmembrane and cytoplasmic regions. LILRA5 is expressed by monocytes, macrophages, and neutrophils (2, 4). It is found as an approximately 40 kDa molecule on the cell surface, while a soluble 25 kDa form can be released into the synovial fluid of rheumatoid arthritis patients (2, 4). Cross-linking of LILRA5 on monocytes induces the expression of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) as well as the anti-inflammatory IL-10 (2, 4). R&D Systems in-house testing indicates that LILRA5 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (5).
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Borges, L. et al. (2003) Blood 101:1484.
- Shiroishi, M. et al. (2006) J. Biol. Chem. 281:19536.
- Mitchell, A. et al. (2008) Eur. J. Immunol. 38:3459.
- Zheng, J. et al. (2012) Nature 485:656.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human LILRA5/CD85f/LIR-9 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: good quality material
Performed binding specificity experiments for the lead molecule (xLILRA6) on its ligand family panels (RA1, RA2, RA5, RA6, RB1, RB2, RB3, RB4, RB5)
